全球心臟药物市场

到 2030 年全球心臟药物市场规模将达到 30 亿美元

全球心臟药物市场规模在 2024 年估计为 10 亿美元，预计到 2030 年将达到 30 亿美元，2024 年至 2030 年的复合年增长率为 19.4%。报告中分析的细分市场之一——洋地黄配糖体，预​​计复合年增长率为 21.6%，在分析期结束时达到 12 亿美元。在分析期内，磷酸二酯酶抑制剂部分预计将以 20.5% 的复合年增长率成长。

美国市场规模估计为 2.847 亿美元，中国市场预计复合年增长率为 26.5%

预计 2024 年美国心臟药物市场价值将达到 2.847 亿美元。预计到 2030 年，作为世界第二大经济体的中国市场规模将达到 7.208 亿美元，在 2024-2030 年分析期内的复合年增长率为 26.5%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 15.3% 和 17.5%。在欧洲，预计德国的复合年增长率约为 16.3%。

全球强心剂市场－主要趋势与驱动因素摘要

为什么强心剂在多种医疗环境中对急性心臟衰竭的管理至关重要？

正性肌力药物主要用于增加心肌收缩力，仍是治疗心臟衰竭、心源性休克和某些心律不整的药物治疗基石。这些药物包括洋地黄配糖体（例如地高辛）、磷酸二酯酶抑制剂（例如米力农）和肾上腺素促效剂（例如多巴酚丁胺），在射血分数降低或心抟出量减少时提供重要的血流动力学支持。儘管出现了新型的心臟衰竭药物，但由于强心药起效迅速、在急性戒断反应中效用，并且在加护治疗和长期心臟衰竭治疗流程中发挥了既定作用，因此仍然具有临床重要性。

在重症监护室或急诊室等急性情况下，强心剂对于稳定危及生命的心臟恶化患者至关重要。在慢性病照护中，选择性药物如地高辛用于控制心率的发生率并减少因射血分数降低的心臟衰竭（HFrEF）住院。

新的药物传递模式和风险管理策略如何促进正性肌力药物的使用？

对毒性和狭窄治疗窗口的担忧，特别是对于地高辛等老药物，历来限制了其广泛使用，但给药方案、治疗药物监测 (TDM) 和个体化治疗方法的进步正在提高安全性和临床结果。静脉注射剂型仍是急性治疗的主要方式，而口服剂型则用于慢性维持治疗。增强的药物安全检测、数位监测工具和针对患者的风险评估模型正在帮助临床医生优化剂量、最大限度地减少不利事件并将安全使用扩展到更广泛的患者群体。

此外，临床试验和观察性研究重新激发了人们对正性肌力药物与 RAAS 抑制剂、SGLT2 抑制剂和β阻断剂的联合策略的兴趣。同时，目前正在研究下一代心肌效率提高、致心律不整风险降低的强心剂，旨在重新定义增强收缩力的药物在现代心臟衰竭治疗中的作用。

哪些领域对正性肌力药物的需求正在成长，哪些临床领域正在引领其应用？

由于心臟衰竭盛行率高、ICU 基础设施强大以及急性护理通讯协定的广泛使用，北美和欧洲仍然是主要市场。静脉注射正性肌力药物在医院的使用仍然很广泛，尤其是在美国。亚太地区的需求成长强劲，尤其是中国、印度和东南亚，这些地区的心血管疾病发病率上升、人口老化以及重症加护机会增多，推动了利用率的提高。

正性肌力药物广泛应用于急性心臟衰竭、术后心臟支持以及其他药物治疗不足的进行性心臟衰竭。高使用率区域包括循环系统房、加护病房、急诊室和心血管手术復健计画。此外，低剂量方案也用于门诊心臟衰竭诊所和老年护理中心特定患者群体的慢性维持治疗。

推动全球心臟药物市场成长的因素有哪些？

随着心臟衰竭盛行率的不断上升、对速效心血管药物的需求不断增长以及急性减压病临床对强心药物和心率控制药物的持续依赖，全球强心药物市场正在不断扩大。随着心臟衰竭治疗变得更加以方案主导和以患者为中心，强心剂仍然是提供血流动力学稳定性和帮助患者进行长期治疗、介入和移植的重要工具。

改进配方、剂量灵活性和安全监测方面的药物创新有助于维持临床信心，而扩大全球获得心臟治疗的机会正在为中低收入国家开闢新的市场。随着医疗保健系统努力应对越来越多的心臟衰竭患者和资源限制，一个关键问题将决定未来：强心剂能否发展出安全性更高、选择性标靶化和组合整合的药物？

部分

药品类型（洋地黄配糖体、磷酸二酯酶抑制剂、心臟保护剂、拟交感神经药、其他药物类型）、给药途径（口服、注射）、剂型（锭剂、溶液、其他剂型）、通路（医院药局、零售药局、网路药局）、用途（心臟手术、心房颤动、心臟心臟衰竭、肺动脉高压、其他用途）

受访企业范例（共34家）

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Fresenius Kabi
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口（成品和OEM）预测公司竞争地位的变化。这种复杂且多方面的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、降低盈利、重组供应链等微观和宏观市场动态。

全球产业分析师密切关注世界领先的首席经济学家（14,949）、智库（62）和贸易及产业协会（171）的专家意见，以评估生态系统的影响并应对新的市场现实。各主要国家的专家和经济学家都在关注关税及其对国家的影响。

全球产业分析师预计，这种动盪将在未来两到三个月内平息，新的世界秩序将更加明确地建立。全球产业分析师正在即时追踪这些发展。

2025年4月：谈判阶段

我们四月份的发布将涵盖关税对全球市场整体的影响，并为各地区的市场调整提供指导。我们的预测是基于历史数据和不断发展的市场影响因素。

2025年7月：最终关税调整

免费更新 在各国宣布最终重置后，本公司的客户将在 7 月收到免费更新。最终更新包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业和领域专家的最具影响力的首席经济学家，他们共用了全球经济状况这一前所未有的模式转移的影响。我们的 16,491 多份报告中的大多数都遵循这个基于两阶段里程碑的发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Cardiotonic Agents Market to Reach US$3.0 Billion by 2030

The global market for Cardiotonic Agents estimated at US$1.0 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 19.4% over the analysis period 2024-2030. Digitalis Glycosides, one of the segments analyzed in the report, is expected to record a 21.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Phosphodiesterase Inhibitors segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.7 Million While China is Forecast to Grow at 26.5% CAGR

The Cardiotonic Agents market in the U.S. is estimated at US$284.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$720.8 Million by the year 2030 trailing a CAGR of 26.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Global Cardiotonic Agents Market - Key Trends & Drivers Summarized

Why Are Cardiotonic Agents Critical in Managing Acute and Chronic Heart Failure Across Diverse Care Settings?

Cardiotonic agents-primarily used to enhance myocardial contractility-remain a cornerstone in the pharmacologic management of heart failure, cardiogenic shock, and certain arrhythmias. These agents, including digitalis glycosides (e.g., digoxin), phosphodiesterase inhibitors (e.g., milrinone), and adrenergic agonists (e.g., dobutamine), provide vital hemodynamic support in cases of reduced ejection fraction or compromised cardiac output. Despite the emergence of novel heart failure therapies, cardiotonic drugs retain clinical importance due to their rapid onset of action, utility in acute decompensations, and established role in both intensive care and long-term heart failure treatment algorithms.

In acute settings such as ICU and emergency departments, cardiotonic agents are essential for stabilizing patients with life-threatening reductions in cardiac function. In chronic care, select agents like digoxin are used for rate control in atrial fibrillation and to reduce hospitalizations in heart failure with reduced ejection fraction (HFrEF), particularly when guideline-directed therapy is inadequate or contraindicated.

How Are New Drug Delivery Models and Risk Management Strategies Enhancing Use of Cardiotonic Therapies?

While concerns around toxicity and narrow therapeutic windows-particularly with older agents like digoxin-have historically limited broader use, advancements in dosing protocols, therapeutic drug monitoring (TDM), and personalized treatment regimens are improving safety and clinical outcomes. Intravenous formulations remain central to acute management, while oral options are used for maintenance therapy in chronic settings. Enhanced pharmacovigilance, digital monitoring tools, and patient-specific risk assessment models are helping clinicians optimize dosage, minimize adverse events, and extend safe usage across broader patient populations.

Clinical trials and observational studies are also driving renewed interest in combination strategies that pair cardiotonic agents with RAAS inhibitors, SGLT2 inhibitors, and beta blockers. In parallel, research into next-generation inotropes with improved myocardial efficiency and lower pro-arrhythmic risk profiles is progressing, aiming to redefine the role of contractility-enhancing agents in modern heart failure care.

Where Is Demand for Cardiotonic Agents Rising and Which Clinical Segments Are Leading Utilization?

North America and Europe remain key markets due to high heart failure prevalence, strong ICU infrastructure, and extensive use of acute care protocols. The U.S., in particular, continues to see widespread use of IV inotropes in hospital settings. Asia-Pacific is witnessing significant growth in demand, particularly in China, India, and Southeast Asia, where rising cardiovascular disease burden, aging populations, and expanding access to critical care are driving greater utilization.

Cardiotonic agents are used extensively in acute heart failure, post-operative cardiac support, and advanced heart failure where other pharmacologic measures are insufficient. High-use segments include cardiology units, intensive care wards, emergency departments, and cardiac surgery recovery programs. Additionally, outpatient heart failure clinics and geriatric care centers use lower-dose regimens for chronic maintenance in selected patient cohorts.

What Is Fueling the Global Growth of the Cardiotonic Agents Market?

The global cardiotonic agents market is expanding in response to the growing incidence of heart failure, increased demand for rapid-acting cardiovascular drugs, and the continued clinical reliance on inotropes and rate-control medications in acute decompensations. As cardiac care delivery becomes more protocol-driven and patient-centered, cardiotonic agents remain essential tools in stabilizing hemodynamics and bridging patients to longer-term therapies, interventions, or transplantation.

Pharmaceutical innovation in formulation refinement, dosing flexibility, and safety monitoring is helping maintain clinical confidence, while expanding global access to cardiac care is opening new markets in lower- and middle-income countries. As healthcare systems grapple with rising heart failure admissions and resource constraints, a critical question defines the future: Can cardiotonic therapies evolve through improved safety, selective targeting, and combinatory integration-while sustaining their frontline role in life-saving cardiac interventions across care settings?

SCOPE OF STUDY:

The report analyzes the Cardiotonic Agents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types); Administration Route (Oral, Parenteral); Dosage Form (Tablet, Solution, Other Dosage Forms); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Actelion Pharmaceuticals Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Fresenius Kabi
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cardiotonic Agents - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Hospitalization Rates for Heart Failure Reinforce Need for Cardiotonic Pharmacotherapy
  • Intravenous Inotropes Remain Standard in Acute Decompensated Heart Failure Management
  • Global Demand Stabilizes for Digoxin and Dobutamine Amid Entry of Next-Gen Cardiotonic Agents
  • Cardiotonic Therapies Integrated Into ICU Protocols for Short-Term Hemodynamic Support
  • Clinical Trials Evaluate Novel Cardiotonic Compounds With Reduced Pro-Arrhythmic Risk Profiles
  • Aging Populations and Comorbidity Prevalence Sustain Chronic Use of Oral Cardiotonic Medications
  • Hospital Formularies Prioritize Cost-Effective, Rapid-Onset Agents in Emergency Cardiac Care
  • Digital Drug Monitoring Tools Improve Safety in Titration and Therapeutic Drug Monitoring
  • Injectable Cardiotonic Agents Gain Inclusion in Global Critical Care Guidelines
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cardiotonic Agents Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cardiotonic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Digitalis Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Digitalis Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cardioprotectants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cardioprotectants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Sympathomimetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Sympathomimetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Solution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Solution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Cardiac Surgical Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Cardiac Surgical Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Heart Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Heart Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Pulmonary Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• JAPAN
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Japan 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• CHINA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 104: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: China 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: China Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: China 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 116: China Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: China 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• EUROPE
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Cardiotonic Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 128: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• FRANCE
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 137: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 140: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: France 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 143: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: France Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: France 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: France Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: France 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 149: France Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: France 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• GERMANY
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 152: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Germany Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Germany 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Germany 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 158: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Germany Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Germany 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Germany Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Germany 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Germany 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 167: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Italy Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Italy 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Italy 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 173: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Italy Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Italy 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Italy Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Italy 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Italy 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 182: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: UK Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: UK 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 185: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: UK 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 188: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UK Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: UK 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 191: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UK Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: UK 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 194: UK Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: UK 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 197: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Spain Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Spain 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Spain 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 203: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Spain Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Spain 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Spain Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Spain 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Spain 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 212: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Russia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Russia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Russia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 218: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Russia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Russia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Russia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Russia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Russia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Europe Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Europe Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Europe Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Asia-Pacific Historic Review for Cardiotonic Agents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 260: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Australia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Australia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Australia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 266: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Australia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Australia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Australia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Australia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Australia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• INDIA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 275: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: India Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: India 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: India 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 281: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: India Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: India 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: India Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: India 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 287: India Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: India 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 290: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: South Korea Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: South Korea 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: South Korea 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 296: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: South Korea Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: South Korea 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: South Korea Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: South Korea 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: South Korea 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 320: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Latin America Historic Review for Cardiotonic Agents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Latin America 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 329: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 338: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Argentina Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Argentina 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Argentina 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 344: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Argentina Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Argentina 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 347: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Argentina Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Argentina 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Argentina 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 353: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Brazil Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Brazil 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Brazil 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 359: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Brazil Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Brazil 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 362: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Brazil Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Brazil 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Brazil 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 368: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Mexico Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Mexico 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Mexico 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 374: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Mexico Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Mexico 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 377: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Mexico Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Mexico 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Mexico 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Latin America Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Latin America Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Latin America Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 398: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 399: Middle East Historic Review for Cardiotonic Agents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Middle East 15-Year Perspective for Cardiotonic Agents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 407: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 416: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Iran Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 418: Iran 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 421: Iran 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 422: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Iran Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 424: Iran 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 425: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Iran Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 427: Iran 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 430: Iran 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 431: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Israel Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 433: Israel 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 436: Israel 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 437: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Israel Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 439: Israel 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 440: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Israel Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 442: Israel 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 445: Israel 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Saudi Arabia Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 448: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Saudi Arabia Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 454: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Saudi Arabia Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 457: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 461: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 462: UAE Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 463: UAE 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 466: UAE 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 467: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 468: UAE Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 469: UAE 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 470: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 471: UAE Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 472: UAE 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 475: UAE 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Rest of Middle East Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 478: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Rest of Middle East Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 484: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Rest of Middle East Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 487: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030
• AFRICA
  • Cardiotonic Agents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 491: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Africa Historic Review for Cardiotonic Agents by Drug Type - Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 493: Africa 15-Year Perspective for Cardiotonic Agents by Drug Type - Percentage Breakdown of Value Sales for Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Cardiotonic Agents by Dosage Form - Other Dosage Forms, Tablet and Solution Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 496: Africa 15-Year Perspective for Cardiotonic Agents by Dosage Form - Percentage Breakdown of Value Sales for Other Dosage Forms, Tablet and Solution for the Years 2015, 2025 & 2030
  • TABLE 497: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Africa Historic Review for Cardiotonic Agents by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 499: Africa 15-Year Perspective for Cardiotonic Agents by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 500: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Africa Historic Review for Cardiotonic Agents by Application - Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 502: Africa 15-Year Perspective for Cardiotonic Agents by Application - Percentage Breakdown of Value Sales for Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Cardiotonic Agents by Administration Route - Oral and Parenteral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Cardiotonic Agents by Administration Route - Oral and Parenteral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 505: Africa 15-Year Perspective for Cardiotonic Agents by Administration Route - Percentage Breakdown of Value Sales for Oral and Parenteral for the Years 2015, 2025 & 2030

IV. COMPETITION